Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.43 |
| ▸ | HTR3B | O95264 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14246929 | 0.81 | CHRM3 (0.62) | HRH3HRH4CHRM3PDE4APDE4B | |
| SCHEMBL28839911 | 0.79 | HRH4 (0.57) | HRH3HRH4CYP1A2HSD17B10HTR2C | |
| SCHEMBL861413 | 0.77 | HRH3 (0.54) | HRH3HRH4CYP1A2HSD17B10PLD1 | |
| SCHEMBL1588027 | 0.75 | HRH4 (0.71) | HRH3HRH4PRKD1PRKD2 | |
| SCHEMBL28124954 | 0.75 | HRH4 (0.59) | HRH3HRH4CYP1A2HSD17B10HTR2C | |
| SCHEMBL1588863 | 0.73 | HRH4 (0.90) | HRH3HRH4 | |
| SCHEMBL28637136 | 0.73 | CASP1 (0.67) | HRH3HRH4CYP1A2HSD17B10PLD1 | |
| SCHEMBL29519526 | 0.73 | CASP1 (0.67) | HRH3HRH4CYP1A2HSD17B10PLD1 | |
| SCHEMBL28125296 | 0.72 | HRH4 (0.66) | HRH3HRH4 | |
| SCHEMBL23458788 | 0.72 | HRH3 (0.65) | HRH3HRH4CYP1A2HSD17B10PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626710-B1 | PROCESS FOR PREPARING AN INTERMEDIATE IN THE SYNTHESIS OF (CYCLOPENTYL[D]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-10870626-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2020-12-22 | — | — | US | disclosed |
| US-10870626-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2020-12-22 | — | — | US | disclosed |
| US-10870626-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2020-12-22 | — | — | US | disclosed |
| EP-3626710-A1 | PROCESSES FOR PREPARING (CYCLOPENTYL[D]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| EP-3626710-A1 | PROCESSES FOR PREPARING (CYCLOPENTYL[D]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-10457648-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | GENENTECH INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457648-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | GENENTECH INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457648-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | GENENTECH INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3197875-B1 | PROCESSES FOR PREPARING (CYCLOPENTYL[D]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2019-08-14 | — | — | EP | disclosed |
| US-20170247338-A1 | PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2017-08-31 | — | — | US | disclosed |
| US-20170247338-A1 | PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2017-08-31 | — | — | US | disclosed |
| EP-3197875-A1 | PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197875-A1 | PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016049414-A1 | PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049414-A1 | PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870626-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | PAK5, CDK5, PPIP5K2 | HRH3 4014/4885HRH4 2925/4885CYP1A2 2217/4885 |
| US-20170247338-A1 | PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | PAK5, CDK5, PPIP5K2 | HRH3 4014/4885HRH4 2925/4885CYP1A2 2217/4885 |
| US-10457648-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | PAK5, CDK5, PPIP5K2 | HRH3 4014/4885HRH4 2925/4885CYP1A2 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.